Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 Dual Target CAR-T in R/R B-cell Lymphoma
NCT04723914Phase 2Unknown
- Sponsor
- Henan Yuli Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19/CD20 dual-target CAR-T cells in B cell lymphoma, sponsored by Henan Yuli Pharmaceutical. Status: unknown.
02
Drugs
CD19/CD20 dual-target CAR-T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04723914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723914.